This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pearson, S.-A. Articles by Ward, R. L. Search for Related Content PubMed PubMed Citation Articles by Pearson, S.-A. Articles by Ward, R. L. Related Articles Related Correspondence

Trastuzumab and Metastatic Breast Cancer: Trastuzumab Use in Australia—Monitoring the Effect of an Expensive Medicine Access Program

Sallie-Anne Pearson, Clare L. Ringland, Robyn L. Ward

From the School of Medicine, University of New South Wales; and the Department of Medical Oncology, St Vincent's Hospital, Sydney, Australia

Address reprint requests to Robyn Ward, MBBS, PhD, Department of Medical Oncology, St Vincent's Hospital, Victoria St, Darlinghurst 2010, Sydney, Australia; e-mail: robyn{at}unsw.edu.au

Purpose: Data from clinical trials are used for drug registration; however, many cancer medicines are ultimately used off-label. This study examines the extent to which the clinical practice use of trastuzumab for the treatment of metastatic breast cancer differs from its use under trial conditions.

Methods: This study involved all women (N = 1,469) with metastatic breast cancer who received trastuzumab in Australia between December 2001 and March 2005. Given that Australia operates a universal health care system, administrative databases could be examined to determine the duration of therapy, rate of off-label use, compliance with cardiac monitoring, and the extent of drug wastage (volume and cost).

Results: A total of 433 enrollees (29.5%) received trastuzumab as monotherapy and 1,036 enrollees (70.5%) received the drug in combination with chemotherapy. A total of 321 women (22%) received off-label trastuzumab. The median duration of trastuzumab therapy was longer than that on trial: 5.6 v 3.1 months for enrollees receiving monotherapy and 12.5 v 6.9 months for concomitant chemotherapy. Only 47 (3%) of enrollees received cardiac monitoring before and during trastuzumab therapy. We estimated 24% of trastuzumab dispensed was discarded, at a cost of $21.1 million Australian. Alternative administration schedules and the addition of another vial size potentially reduce wastage to 6% of volume dispensed.

Conclusion: Debates about the use of expensive cancer medicines should consider postmarketing assessments as well as trial experience. The longer duration of trastuzumab use in clinical practice and the high rates of off-label use provide incentive for new clinical trials. Strategies to improve cardiac monitoring and to minimize drug wastage are issues that require immediate attention.

Supported by patient donations to St Vincent's Hospital, Sydney, and the Population Health and Use of Medicines Unit, St Vincent's Hospital and University of New South Wales; the Cancer Institute, New South Wales (S.P.).

R.W. is a member of the Pharmaceutical Benefits Advisory Committee, Australia. The views expressed in the manuscript do not represent those of this committee.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Related Correspondence

• Use of Trastuzumab for Metastatic Breast Cancer in Australia: Inaccurate Results and Alternative Interpretation of Findings
  Arlene Chan and Richard de Boer
  JCO 2007 25: 5662-5663 [Full Text]

This article has been cited by other articles:

				A. Chan and R. de Boer Use of Trastuzumab for Metastatic Breast Cancer in Australia: Inaccurate Results and Alternative Interpretation of Findings J. Clin. Oncol., December 10, 2007; 25(35): 5662 - 5663. [Full Text] [PDF]